Tuesday
January 16,2018

CYTOS BIOTECHNOLOGY

http://www.kuros.ch/



Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

CEO

Didier Cowling

Phone:
41 (0)44 200 56 00

Email:
info@kuros.ch

Profile: